Seeking to enable novel discoveries in cancer biology, leading to novel, personalized treatment options in cancer, Indivumed, a science-led, integrated global oncology company, and Personalis today announced that the two companies have entered into a collaboration in the field of personalized oncology.

The partnership focuses on pairing IndivuType, Indivumed’s multiomics cancer database, with genome and transcriptome-level data from thousands of samples using Personalis’ advanced cancer genomics technology.

Hartmut Juhl, M.D., Ph.D., is an entrepreneur, surgical oncologist, and world-renowned researcher dedicated to the science of tissue quality and its application to precision medicine in cancer diagnostics and therapeutics. Photo Courtesy: © 2020 Indivumed GmbH

“Genomics and transcriptomics play a crucial role in truly understanding cancer biology,” said Hartmut Juhl, M.D., Ph.D. Chief Executive Officer and founder of Indivumed.

“Adding Personalis’ technology to the IndivuType multiomics profile will enable relevant discoveries in our collaborations with pharma and biotech and further our mission to advance precision oncology,” Juhl added, who Hartmut holds a professorship at the Medical Faculty of Hamburg University, is an adjunct professor at the Lombardi Cancer Center of Georgetown University, and has served as an advisor to the U.S. National Cancer Institute on matters of tissue quality for clinical and research applications.

Valuable Data
The IndivuType database provides high-quality samples that enable analysis beyond genomics to include transcriptomics, proteomics, phosphoproteomics and immunophenotyping in combination with clinical and outcome data that makes it a powerful resource for the cancer community.

Pairing these high-quality samples with Personalis’ innovative and robust solutions for comprehensive tumor genomics characterization has the potential to provide deeper insights into oncology therapeutics.

“Working with Indivumed on this program will allow us to deliver broad, more comprehensive genomic sequencing for cancer that can ultimately fuel drug discovery and development,” said John West, Chief Executive Officer of Personalis.

“Pairing Indivumed’s leading position as a premier quality clinical cancer biobank with our extensive genomics experience will result in one of the most comprehensive multiomics cancer databases in the world,” West added.

More importantly, we feel these databases will provide the insights needed to drive precision medicine in oncology. This new offering leverages Personalis’ extensive whole-genome sequencing experience, including laboratory automation and data systems developed for the U.S. Department of Veterans Affairs for the VA Million Veterans Program, and our expertise in processing tumor samples as part of large-scale oncology translational research projects with our biopharma partners.”

The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited.

More Info
ASCO 2019: Form Biomarker Discovery to Photo-Immunotherapy – The Onco’Zine Brief [Radio Program]